RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression Pharmaceutical Investing
Knight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig(R) in Canada and Israel Life Science Investing
Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer Treatment Pharmaceutical Investing
Catalyst Pharmaceuticals Announces First Patient Enrolled in Second Phase 3 Trial of Firdapse in Lambert-Eaton Myasthenic Syndrome Pharmaceutical Investing
Argenx Launches Phase I/II Study of ARGX-110 in Combination with Azacitidine Pharmaceutical Investing
Bayer Announces FDA Acceptance of Supplemental Biologics License Application for myBETAapp™ and BETACONNECT™ Navigator Pharmaceutical Investing
